Evidence map›Paper›PMID 36454263›Full record

Trial reportNucleic acid therapeutics2023

Integrated Assessment of Phase 2 Data on GalNAc

Brenda F Baker, Shuting Xia, Wesley Partridge, T Jesse Kwoh, Sotirios Tsimikas, Sanjay Bhanot, Richard S Geary

Open access · hybridAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nucleic acid therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. On-treatment platelet reactivity through the thromboxane AJournal of thrombosis and thrombolysis · 2023
    Trial
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Brenda F BakerDepartment of Drug Development, Ionis Pharmaceuticals, Carlsbad, California, USA.
Shuting XiaDepartment of Drug Development, Ionis Pharmaceuticals, Carlsbad, California, USA.
Wesley PartridgeDepartment of Drug Development, Ionis Pharmaceuticals, Carlsbad, California, USA.
T Jesse KwohDepartment of Drug Development, Ionis Pharmaceuticals, Carlsbad, California, USA.
Sotirios TsimikasDepartment of Drug Development, Ionis Pharmaceuticals, Carlsbad, California, USA.
Sanjay BhanotDepartment of Drug Development, Ionis Pharmaceuticals, Carlsbad, California, USA.
Richard S GearyDepartment of Drug Development, Ionis Pharmaceuticals, Carlsbad, California, USA.
Ionis Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Receptor-mediated delivery of an antisense oligonucleotide (ASO) using the ligand-conjugated antisense technology is establishing a new benchmark for antisense therapeutics. The triantennary

Indexed as

HepatocytesOligonucleotides, AntisenseHumansLigandsOligonucleotidesRNALigandsOligonucleotidesOligonucleotides, AntisenseRNAintegrated safety analysisligand-conjugated antisense technologyphase 2randomized placebo-controlled trialstriantennary N-acetylgalactosamine

Identifiers

PMID36454263
PMCPMC10623620
OpenAlexW4310566139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.